MAM
Omnicom Group’s Annalect India elevates its executive leadership team
Annalect India on Thursday announced the elevation of their executive leadership team in India. The company will be completing their 10-year milestone journey in India this August as Omnicom’s delivery and capability centre. Annalect India currently has four centres of excellence in Gurugram, Bengaluru, Chennai, and Hyderabad, with a strength of over 1200+ employees in the field of Tech, creative services, marketing science, media and global shared services.
Effective immediately, Vishal Srivatsava, former president, Annalect India, will be taking up the role of chief executive officer, Annalect India.
In addition, Annalect India is launching three key organizations to drive growth and efficiency in the business outcomes and promoting leaders to take the charge of each.
Operations Organization: Kiran Guruswami has been a partner in the growth journey from day one of Annalect India’s inception for the last 10- years and he will take charge as the chief operating officer. All business units including media services, marketing science, technology services, creative services, global shared services and governance will report to him.
Client Success Organization: Kaushik Srinivasan will take charge as the chief client officer. This team will be responsible for driving our exponential growth and engaging with clients and Omnicom agencies to drive current and emerging capabilities.
People and Culture Organization: Devya Patney will take charge as the chief people and culture officer. All people-centric units (employee experience, talent transformation, talent acquisition, HR services & tech, Annalect India academy, administration, employer branding & communication) will report to her.
All the above leaders will continue to report to Vishal Srivastava.
Speaking on the occasion, Annalect Group chief financial officer & chief operating officer Steve Tobengauz said, “We will be celebrating our 10-year anniversary this August. So far this year, we have witnessed immense growth in talent, and support from Omnicom Group partners. We are confident of our strategy given the solid results and are going to double this year and expected to quadruple in next few years.
Our vision will require us to rethink our operating model, and ways of working. To help lead through this we are initially focusing on evolving our leadership structure to ensure that our people, agency partners and clients are supported. Vishal and the executive leadership team have been instrumental in the company’s success. I’m inspired by Vishal’s leadership with genuine concern for our people and culture. It goes without saying that none of this would be possible without the support of the entire rockstar Annalect India management team.”
Newly elevated Vishal Srivastava added, “I take immense pride and satisfaction in leading such an amazing group of talent at Annalect India. As I take on the role of CEO, I also believe it takes a team to get the job done and support from everyone as we work towards it. I am privileged and thankful to be surrounded by great leaders in this organization. We are excited about the great future of our organization and the business value it delivers to Omnicom agencies and their clients”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
